"Gene Alterations Predict Response To Immunotherapy In Urothelial Carcinoma"
Alterations in DNA damage repair and response genes appear to improve response to immune checkpoint blockade among patients with urothelial carcinoma, according to findings presented at the ASCO Annual Meeting. These results “clearly” indicate that such alternations could be “a potential predictive biomarker for response to immune checkpoint blockade,” says Matthew Galsky, MD, associate professor of medicine, hematology and medical oncology, assistant professor of urology and the director of genitourinary medical oncology at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “This is not ready for prime time, but there are ongoing, randomized clinical trials in the first-line setting in urothelial cancer, randomizing patients to chemotherapy alone vs. chemotherapy plus immune checkpoint blockade,” Dr. Galsky said. “Those cohorts are ideally suited for testing this biomarker question.”
- Matthew Galsky, MD, Associate Professor, Medicine, Hematology and Medical Oncology; Assistant Professor, Urology; Director, Genitourinary Medical Oncology, The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai